2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Glioma
4
Glioblastoma
4
Melanoma
3
Leukemia, Myeloid, Acute
3
Sarcoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Astrocytoma
2
Treatment
1
Stomach Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Rhabdomyosarcoma
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Neurofibrosarcoma
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms
1
Neoplasm Metastasis
1
Myosarcoma
1
Microsatellite Instability
1
Lung Neoplasms
1
Liposarcoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Leiomyosarcoma
1
Interventions
Carboplatin
8
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Observation
3
Neoadjuvant Therapy
3
Epirubicin
3
Endoscopy
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
130-nm albumin-bound paclitaxel
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
lentiviral minigene vaccine of COVID-19 coronavirus
×
Clear all
NCT01686334
2024-03-12
WIDEA
University Hospital, Antwerp
Phase 2
Active not recruiting
130 enrolled